Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
…, M Rickenbach, L Dal Maso, O Keiser… - Journal of the …, 2005 - academic.oup.com
Background: Persons infected with human immunodeficiency virus (HIV) have an increased
risk for several cancers, but the influences of behavioral risk factors, such as smoking and …
risk for several cancers, but the influences of behavioral risk factors, such as smoking and …
Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi
… Haas and Olivia Keiser contributed equally to the writing of this article. Correspondence to
Olivia Keiser, PhD, Institute of Social and Preventive Medicine (ISPM), Finkenhubelweg 11, …
Olivia Keiser, PhD, Institute of Social and Preventive Medicine (ISPM), Finkenhubelweg 11, …
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
…, S Schrempft, K Marcus, S Yerly, IA Vernez, O Keiser… - The Lancet, 2020 - thelancet.com
Background Assessing the burden of COVID-19 on the basis of medically attended case
numbers is suboptimal given its reliance on testing strategy, changing case definitions, and …
numbers is suboptimal given its reliance on testing strategy, changing case definitions, and …
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes
Background Prognostic models have been developed for patients infected with HIV-1 who
start combination antiretroviral therapy (ART) in high-income countries, but not for patients in …
start combination antiretroviral therapy (ART) in high-income countries, but not for patients in …
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies
Background Few estimates exist of the life expectancy of HIV-positive adults receiving
antiretroviral treatment (ART) in low- and middle-income countries. We aimed to estimate the life …
antiretroviral treatment (ART) in low- and middle-income countries. We aimed to estimate the life …
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
Background Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450
2B6 (CYP2B6). Allele 516 G> T (Gln172His) is associated with diminished activity of this …
2B6 (CYP2B6). Allele 516 G> T (Gln172His) is associated with diminished activity of this …
[PDF][PDF] Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
…, M Schechter, C Laurent, O Keiser… - Bulletin of the World …, 2008 - SciELO Public Health
OBJECTIVE: To analyse the early loss of patients to antiretroviral therapy (ART) programmes
in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (…
in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (…
[HTML][HTML] Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland
The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen
and is key to characterising the severity of infection across the population and for specific …
and is key to characterising the severity of infection across the population and for specific …
Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study
…, A Calmy, M Cavassini, B Ledergerber, O Keiser - British journal of …, 2010 - nature.com
Background: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a
decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but …
decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but …
Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub‐Saharan Africa: systematic review and meta‐analysis
Objectives To assess the proportion of patients lost to programme (died, lost to follow‐up,
transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub‐…
transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub‐…
